Novavax, Inc. (NASDAQ:NVAX) released its financial results for the last quarter on 02/27/2017. The company traded a total of 3.86 Million shares in the previous session. The stock opened at 1.29 and closed at 1.22. The stock recorded a stock decrease of -4.69%
Analysts set the price target for the company at 12. The company reported the one year price target of 3.58.
Investors expected a price target of -0.13 for this quarter. Zacks Investment Research gave Novavax, Inc. a rating of 2.67 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.
Going by this performance, the stock has the ability to reach a high EPS of -0.13 on every share and a low EPS of -0.19 on every share in this quarter. 7 analysts concur with these earnings estimates.
For the quarter ending 11/09/2016, The Analyst projected that the company could deliver EPS of -0.26 while the company provided its Actual EPS of -0.24 showing a difference of 0.02 Percent between the Estimated and Actual EPS. Hence, the surprise factor was 7.7 percent.
For the previous quarter, analysts recommended $-0.23 per share but the company recorded an Actual EPS of $-0.21 per share representing a difference of 0.02% and a surprise of 8.7%
The five analysts covering the company have an average target of 1.50 with the highest estimate being 12.00 while the lowest is 1.50. The average estimate represents a +22.95% raise from last year’s price of 1.22.
The highest estimate in the current quarter is 9 million while the lowest is 4 million. The analysts are also projecting average revenue of 6.17 million compared to the company’s last year sales of 4.22 million.
The company has showed a 39.8% rise in sales growth. Novavax, Inc reported a 52-week high price target of 8.49 on September 15, 2016 and a 52-week low of 1.16 on September 16, 2016.
The stock has a market cap of 337.05 Million. The rate of volatility stands at 4.00% and 4.32% each.